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Summary Anticipatory nausea and vomiting (ANV) after repeated cycles of cytotoxic chemotherapy is
thought to be a conditioned response to a conditioning stimulus. Good control of acute and delayed emesis
may result in a lower incidence of ANV. We have analysed data from 574 chemotherapy patients who received
granisetron as their antiemetic treatment during repeat cycle chemotherapy. Per treatment cycle, less than 10%
ofpatients displayed symptoms of anticipatory nausea and 2% or less had symptoms of anticipatory vomiting.
It is concluded that the use of granisetron as an antiemetic during the acute phase of chemotherapy may result
in a lower incidence of ANV in patients undergoing repeat cycle chemotherapy.
The treatment of many forms of malignant disease often
involves the use of cytotoxic agents whose toxic effects in-
clude nausea and/or vomiting. Andrykowski et al. (1985)
showed that, in patients undergoing the initial phase of
chemotherapy, emesis is an unconditioned response. How-
ever, after a few cycles of emetogenic chemotherapy during
which the patient experiences emesis, the association of fac-
tors linked with chemotherapy (visual, gustatory, olfactory,
environmental) may themselves initiate emesis. These factors
are considered to be conditioned stimuli eliciting a condi-
tioned response (emesis). Typically, these factors may precipi-
tate emesis prior to the administration of chemotherapy, and
this emesis is referred to as anticipatory nausea and vomiting
(ANV). The incidence of ANV may vary widely from centre
to centre owing to heterogeneity of patients and treatments.
Early reviews of the prevalence of ANV showed that it
ranges from 28.3% (Nicholas, 1982) to 44% (Nesse et al.,
1980). Love et al. (1982) reported a prevalence of anticipa-
tory vomiting of 38%. The percentage of patients who
reported ANV was subdivided by Morrow et al. (1982) into
24% who experienced anticipatory nausea and 9% anticipa-
tory vomiting. The relationship between the development of
ANV and the number of chemotherapy treatments has also
been documented (Redd & Andresen, 1981; Nicholas, 1982;
Redd et al., 1982).
Chang (1981) showed that ANV is poorly responsive to
treatment with conventional antiemetics, and much effort has
been put into understanding the aetiology of ANV by Mor-
row et al. (1991). Behavioural treatment (Morrow & Morrell,
1982) to desensitise patients by means of counselling or by
relaxation techniques has been considered.
It is now accepted that the development of ANV is a
function of the emetogenicity and frequency ofchemotherapy
treatments. In a study by Wilcox et al. (1982), prevention of
post-chemotherapy nausea and vomiting by conventional
antiemetics was associated with the prevention of symptoms
of ANV. The recent introduction of the potent and selective
5-HT3 antagonists as antiemetics (granisetron, ondansetron
and tropisetron) has been regarded as being a significant
advance in the control of acute emesis. In this paper we
analyse the incidence of the symptoms of ANV of patients
who have undergone repeat cycles of moderately emetogenic
chemotherapy and who received granisetron as their
antiemetic treatment.
Materials and methods
Chemotherapy-naive patients who had given their informed
consent were entered into one of several large multicentre,
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multinational antiemetic studies involving granisetron.
Patients received granisetron under a continuation protocol
for their successive chemotherapy treatment, provided that
this did not change. This report relates to those patients
treated within this continuation protocol. These antiemetic
studies and the continuation protocol conformed to the Dec-
laration of Helsinki (Hong Kong Amendment 1989) and
were reviewed by the ethics review boards of each par-
ticipating centre prior to the commencement of the study. A
10% variation in chemotherapy dose was allowed for
changes in patient weight between cycles. The cytotoxic
regimen had to include at least one of the following
inravenous agents given as a single dose on day 1 of the cycle
of chemotherapy: carboplatin >300 mg m-2; cisplatin
>20 mg m-2; cyclophosphamide >600 mgm-2 i.v. when
given in combination with other agents; dacarbazine
>350 mg m-2 and <500 mg m-2; doxorubicin >40 mg m-2
as a single agent or >25 mg m-2 in combination with other
cytotoxic agents; epirubicin >75 mg m2 as single agent or
> 50 mg m-2 in combination with other agents; mustine
>6mgm2. Other cytostatic agents were administered con-
currently with one of the above chemotherapy agents.
Granisetron was administered 10 min before chemotherapy
to each patient as a 40gAg kg'- intravenous infusion of 20 ml
of 0.9% sodium chloride solution over 5 min. In the event of
nausea and vomiting during the first 24 h, one or two (but
not more) additional doses of granisetron (40;Lg kg-') could
be given, at least 10 min apart. Standard antiemetics could be
given if granisetron failed to control the symptoms of nausea
and vomiting. Patients were entered into the trial if they
satisfied the following criteria: they must have already com-
pleted a cycle of chemotherapy in a granisetron study and
wish to receive granisetron treatment with subsequent cycles
of the chemotherapy; a minimum age of 16 years; ability to
comply with protocol procedures; and ability to give in-
formed consent. Patients were excluded if they had suffered a
serious adverse event suspected of being caused by graniset-
ron; if they had marked hepatic or renal dysfunction, an
active peptic ulcer, gastric compression or tumour involve-
ment likely to lead to subacute obstruction; if they had
received any other investigational drug within the past 3
months or were due to receive such drugs during this cycle of
chemotherapy; if there had been changes in their chemo-
therapy other than a dose reduction.
Patients were allowed to continue to take previous CNS
medication but not to start treatment with these drugs
because of their amnesic effects. They were all hospitalised
for a minimum period of 2 h following the administration of
their chemotherapy. Clinical and laboratory monitoring was
carried out in the patients immediately before, during and
after their chemotherapy treatment.
Subjective assessments of acute nausea and vomiting were
made retrospectively every 6 h by the patient beginning at the
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start of chemotherapy for 24 h. Nausea was rated as either
none, mild, moderate or severe. Vomiting (including retching)
was recorded as either no episodes, one episode, 2-4
episodes or more than four episodes.
The extent of anticipatory nausea and vomiting was
assessed according to the number of patients who reported
symptoms of nausea and/or vomiting within the first 6 h
prior to receiving chemotherapy.
Antiemetic efficacy was defined as follows. A complete
response was deemed to have been achieved if patients
experienced no worse than mild nausea with no vomiting. A
major response was recorded if patients experienced
moderate to severe nausea but no more than one vomiting
episode in the first 24 h following the start of chemotherapy.
For the purposes of this report all other remaining patients
were considered to be failures.
Results
A total of 574 patients were entered into the continuation
protocol, all of whom had previously completed a cycle of
chemotherapy. In the majority of patients, granisetron had
been given as antiemetic treatment during the previous cycle
of chemotherapy. However, 75 patients had received a com-
parator antiemetic during their first cycle of chemotherapy
and consequently received granisetron for the first time on
cycle 1 of this study. Of the 574 patients, 571 were entered at
either cycle 1 or cycle 2, while the remaining three patients
were entered at later cycles. All patients underwent moder-
ately to highly emetogenic chemotherapy, including 215
patients who received cisplatin (mean dose >82 mgm-2).
Patient demographic details are shown in Table I and include
the number of patients per treatment cycle and gender. The
ratio of female to male patients increased during the study
and may indicate that more chemotherapy sessions are
required to treat female patients. Over all cycles of graniset-
ron, the chemotherapy dosage was changed in 77 patients,
being, on average, 10% higher than that given on their first
cycle of chemotherapy. The reasons for the change in dosage
were to achieve a better tumour response or because the
patient had gained weight or because of an error in the
original dosage.
Details of patients who were withdrawn from the study are
listed in Table II. Of these patients, 90 were withdrawn for
unknown reasons, 245 were withdrawn because of com-
pletion of chemotherapy treatment and 54 were withdrawn
because of treatment with an alternative antiemetic, 18 of
whom were withdrawn on the second cycle of granisetron
treatment. Forty-one patients had significant changes to their
chemotherapy which warranted withdrawing the patients
from the study. Twenty-four patients refused treatment or
were lost to follow-up, including nine who died. Thirty-two
patients were withdrawn for various other reasons. Only one
patient was withdrawn from the study because of vomiting
prior to chemotherapy. No patients were withdrawn because
of serious adverse events attributable to granisetron. Eighty-
four patients listed as not withdrawn were transferred to
another granisetron protocol for continuation treatment.
Antiemetic efficacy results including the number ofpatients
who required additional antiemetic therapy are given in
Table III. The proportions of patients considered to be com-
plete responders are recorded. Details of patients requiring
additional antiemetic (including additional granisetron)
therapy are also given. Patients who were classified as having
a complete response were not given alternative antiemetic
treatment.
The results suggest that a consistent complete response rate
over 59% was seen in this cohort of patients. The proportion
of patients requiring additional granisetron remained almost
constant in each cycle of treatment. In cycles containing
more than 100 patients, a mean of 19% of the patients
(range 17-23%) required additional doses. However, there
was an increasing trend for the need for a second additional
dose of granisetron as chemotherapy cycle numbers in-
creased. The proportion of patients requiring additional
antiemetic therapy other than granisetron also increased by a
small extent with increasing number of chemotherapy treat-
ments. The mean percentage of patients requiring additional
antiemetics other than granisetron (in cycles containing more
than 100 patients) was found to be 8% (range 4-13%).
The numbers of patients who had nausea and/or vomiting
prior to chemotherapy are shown in Table IV. Of the 574
patients entered into the study, 37 patients were recorded as
having symptoms of ANV on 50 occasions. Thirty-six
patients presented with ANV during the first six granisetron
treatment cycles, and one patient during the ninth treatment
cycle. Of these 37 patients who displayed symptoms of ANV
prior to chemotherapy, 27 were females and 10 were males.
This ratio reflects the greater proportion of females remain-
ing for consecutive cycle chemotherapy. Anticipatory nausea
with vomiting was reported by eight patients, while 22
Table I Summary of patient demographic details
Cycle of granisetron
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
No. of patients 75 512 373 224 147 108 27 17 10 7 5 5 1 1 1
Male 38 243 143 74 45 29 8 5 2 2 2 2
Female 37 269 230 150 102 79 19 12 8 5 3 3 1 1 1
Table II Summary of withdrawals
Cycle of withdrawals
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
No. of patients 75 512 373 224 147 108 27 17 10 7 5 5 1 1 1
Reason for withdrawal
Unknown 8 43 22 9 3 1 1 1 2
Completed course of 2 55 69 27 16 61 4 6 1 2 2
chemotherapy
Alternative antiemetic 4 18 15 11 4 1 1
regimen
Changes in chemotherapy 1 15 12 6 3 4
- not dose decrease
Patient refusal/lost 0 8 6 5 0 3 2
to follow-up/death
Other 1 15 8 6 2 2 0 1 1
Withdrawna 16 154 132 64 28 72 8 7 3 2 0 4 0 0 0
aEighty-four patients were transferred to a different granisetron protocol for further treatment.EFFECT OF GRANISETRON ON ANV 959
Table III Summary of antiemetic efficacy
Cycle of granisetron use
1 2 3 4 S 6 7 8 9 10 11 12 13 14 15
No. of patients 75 512 373 224 147 108 27 17 10 7 5 5 1 1 1
Complete responders 52 342 233 139 88 66 19 10 6 6 4 4 1 1 1
(%) (69) (67) (62) (62) (60) (61) (70) (59) (60) (86) (80) (80) (100) (100) (100)
Additional doses of
granisetron (no. of
patients)
One dose 11 58 40 20 11 6 1 2 1 1 0 0 0 0 0
Two doses 6 36 24 24 16 12 1 0 0 0 0 0 0 0 0
Additional antiemetic 3 33 23 23 19 10 1 1 0 0 0 0 0 0 0
therapy other than
granisetron (no. of
patients)
Table IV Summary of patients receiving granisetron and reporting nausea and/or vomiting prior to chemotherapy
by cycle
Cycle of granisetron use
1 2 3 4 5 6 7 8 9 Overall
No. of patients 75 512 373 224 147 108 27 17 10 574
No. with only nausea 0 7 7 6 7* 3 0 0 1 31
prior to chemotherapy (%) (1.3) (1.9) (2.6) (4.8) (2.8) (10)
No. with only vomiting 0 0 0 1 3* 0 0 0 0
prior to chemotherapy (%) (0.4) (2.0)
No. with vomiting and 1 2 3 2 3 4** 0 0 0 15
nausea prior to (1.3) (0.3) (0.5) (0.9) (2.0) (3.7)
chemotherapy (%)
No. with any anticipatory 1 9 10 9 13*** 7* 0 0 1 50
symptoms (1.3) (2.0) (4.0) (4.0) (8.8) (6.5) (10)
Chi-square test: *P<0.05, **P<0.010, ***P<0.001.
patients reported anticipatory nausea (AN) only and three
patients had AN in one cycle and anticipatory nausea with
vomiting in another. Three patients had anticipatory
vomiting (AV) without nausea and one had AV in one cycle
and ANV in another cycle. Thirty out of the 37 patients who
experienced ANV had some prior emesis during the acute
phase of one or more of their previous chemotherapy ses-
sions, though delayed emesis (nausea and or vomiting) had
been experienced in the post-acute phase by most patients.
Symptoms of ANV developed after a median of 4-5 cycles
of chemotherapy, and were experienced for a median of only
one chemotherapy cycle. Twenty-seven patients reported
symptoms of ANV on one session, eight patients on two
sessions and only two patients reported symptoms of ANV
on three sessions. All patients who displayed ANV received
moderate to highly emetogenic chemotherapy, including cis-
platin plus cyclophosphamide (13 patients), anthracyclines
plus cyclophosphamide (12 patients), cisplatin alone or
cisplatin-containing chemotherapy regimens (five patients) or
carboplatin-containing regimens (two patients), while the
remaining five patients received combinations of cyclophos-
phamide, anthracyclines or other agents. Less than 9% of the
patients in each treatment cycle (excluding cycle 10)
experienced nausea and/or vomiting prior to chemotherapy.
A progressive increase in the numbers of patients with symp-
toms of ANV per chemotherapy cycle was noted, while the
treatment group size decreased progressively. This suggested
that nausea and vomiting prior to chemotherapy may be
related to the number of treatments given to each patient and
subsequent exposure to emetogenic stimuli. An analysis of
the proportion of patients presenting with anticipatory symp-
toms at cycles 5 and 6 compared with cycle 2 showed that
there were significant increases in AN and AV (at cycle 5)
and ANV at cycle 6. Other comparisons were not signifi-
cantly different. Of 50 occasions on which any anticipatory
symptoms were reported, there were only six on which the
acute symptoms of nausea and vomiting were completely
controlled by granisetron; ten were considered as major
responses, while the remaining occasions were considered
failures.
Discussion
This study was a retrospective longitudinal study with no
control group, raising the possibility of a selection bias in
favour of good responders. Poorly responding patients were
generally offered alternative treatment on their next session
in the hope of improving their clinical response. Some
patients who were withdrawn from this study and given
alternative antiemetics might have had severe emesis as a
basis for withdrawal from the study. It is possible that a
proportion of these patients may have developed symptoms
of ANV on later chemotherapy cycles. However, an analysis
of the Swiss data from this study by Kirchner et al. (1993)
showed that, of the four Swiss patients withdrawn and given
alternative antiemetics, only two were withdrawn because of
poor antiemetic efficacy, while the remainder received alter-
native antiemetics for other reasons. Conversely, several
patients considered to be treatment failures continued to
receive granisetron on successive chemotherapy cycles. Study
continuation or withdrawal was thus not always indicative of
the patient's prior response to antiemetic treatment.
In this study, the weighted mean of the complete response
rate for all cycles in those patients receiving a moderately
emetogenic regimen was found to be 65%, which suggests
that antiemetic efficacy was maintained on all cycles of treat-
ment throughout chemotherapy. The increased use of addi-
tional dosages of granisetron as rescue antiemetic therapy
may reflect the increase in severity of the symptoms of
nausea and vomiting. Our data showed that fewer males
continued into the study, but, with respect to ANV, the ratio
of males to females remained similar to the ratio observed in
patients without ANV. The apparent selection of female
patients appears to be a consequence of selection due to
chemotherapy treatment (adjuvant use for breast cancer and
protocols for ovarian cancer) rather than antiemetic
response.
Twenty-six patients who displayed symptoms of ANV did
so after receiving cyclophosphamide-containing chemo-
therapy, and an association between these two factors cannot
be discounted. Reporting results by cycle, rather than960 M.S. AAPRO et al.
cumulatively, may represent a more favourable picture, since
some withdrawn patients (including 22 who had already
presented with ANV) may present with ANV on their subse-
quent chemotherapy sessions. Consistent with the findings of
Chang (1981) was that ANV symptoms were poorly respon-
sive to therapy. Six patients had developed symptoms of AN
and/or AV despite being classified as complete responders
during the acute phase of prior chemotherapy cycles. Inspec-
tion of the patient records showed that four of these six
patients had experienced symptoms of delayed emesis within
72 h of the start of chemotherapy on prior chemotherapy
cycles, though in one case this was mild nausea. The fifth
patient changed to alternative antiemetics on session 2, but
returned to granisetron for further sessions, suggesting that
conventional antiemetics may not have controlled emesis dur-
ing session 2. All other patients who had ANV were con-
sidered either as failures (25 patients) or as major responders
(six patients) on previous cycles during the acute treatment
phase, therefore reinforcing the paradigm that ANV is a
function of prior history of emesis. Only one patient had
symptoms of ANV (both nausea and vomiting) prior to their
first treatment session, though was considered to be a com-
plete responder during the acute phase of the study. The
recorded data from this study do not allow us to draw a
conclusion with respect to the relationship between the
incidence of delayed nausea and vomiting and ANV, though
it is likely that delayed nausea and vomiting may play a role
in the emergence of ANV. The onset of ANV required a
median of 4-5 chemotherapy treatment cycles, in agreement
with published data (Nicholas, 1982; Redd & Andresen,
1991). The percentage of patients with ANV per treatment
cycle remained low: a maximum prevalence of 4.8% for
anticipatory nausea and 3.7% for anticipatory vomiting up
to session 6 was found. Literature sources document that
after multicycle chemotherapy treatment the prevalence of
ANV may be as high as 25-40%. Morrow and Morrell
(1982) found that, of 406 chemotherapy patients, 81 (20%)
had mild to intolerable nausea, and 35 (8.6%) had had
vomiting prior to their chemotherapy. Our results show that
the use of granisetron may have resulted in fewer patients
displaying symptoms of ANV, though these results may be
confounded by the selection of good responders during the
study. It is also possible that some of the patients withdrawn
during the study may have developed ANV on their follow-
ing chemotherapy treatment cycle, therefore the observed
positive effects of granisetron may be inflated.
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